Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of $0.22, $0.18 better than the analyst estimate of $0.04. Revenue for the quarter came in at $33.75 million versus the consensus estimate of $18.7 million.

GUIDANCE:

Protalix BioTherapeutics sees FY2026 revenue of $78-83 million, versus the consensus of $79.1 million.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.